Recordati Industria Chimica e Farmaceutica SPA (IT:REC)
:REC
Want to see IT:REC full AI Analyst Report?
REC Stock Chart & Stats
€50.40
€0.75(1.43%)
At close: 4:00 PM EST
€50.40
€0.75(1.43%)
Day’s Range― - ―
52-Week Range€43.76 - €55.35
Previous CloseN/A
Volume283.52K
Average Volume (3M)218.69K
Market Cap
€10.50B
Enterprise Value€12.46B
Total Cash (Recent Filing)€380.47M
Total Debt (Recent Filing)€2.37B
Price to Earnings (P/E)22.0
Beta0.53
Next Earnings
Jul 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.67%
Share Statistics
EPS (TTM)2.30
Shares Outstanding209,125,150
10 Day Avg. Volume203,691
30 Day Avg. Volume218,687
Financial Highlights & Ratios
PEG Ratio3.24
Price to Book (P/B)5.20
Price to Sales (P/S)3.81
P/FCF Ratio19.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€57.50Price Target Upside14.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)3.19
Revenue Forecast (FY)€2.79B
Bulls Say, Bears Say
Bulls Say
High Profitability And MarginsSustained high gross and EBITDA margins imply durable pricing power and efficient cost structure, enabling the firm to fund R&D, specialty commercialization, and dividends. These margins provide a structural buffer versus cyclical revenue swings and support long-term returns on capital.
Significant Revenue Scale And GrowthNear-€2.7B scale with positive mid-single-digit to high-single-digit growth supports market positioning and investment capacity. Size enables fixed-cost absorption, broader commercial reach across geographies, and greater negotiating leverage with payors and partners over the medium term.
Diversified Specialty And Rare-Diseases ModelA two‑pillar model combining branded primary-care franchises and orphan therapies reduces concentration risk and improves revenue durability. Rare-disease products typically enjoy specialized channels and pricing/ reimbursement protections, supporting steady cashflows and strategic premium margins over time.
Bears Say
Elevated LeverageDebt-to-equity near 1.15 constrains financial flexibility for M&A, buybacks, or cushioning against adverse reimbursement shifts. Elevated leverage raises interest-service risk and reduces the company's ability to absorb prolonged cash-flow shortfalls without tightening investment or capital returns policies.
Weaker Cash Conversion And Declining FCFDeclining FCF and OCF materially below accounting profit point to working-capital or timing pressures that can tighten reinvestment capacity. Persistent cash conversion weakness limits organic funding for R&D, commercialization in new markets, and reduces margin of safety for dividends or debt reduction.
Sustainability Of Recently High Growth UncertainAn atypical step-up in growth raises the risk that part of recent gains are nonrecurring. If new-product momentum, pricing or one-off items fade, revenue and margin forecasts could revert, stressing planning, investment returns, and potentially exposing the company to sharper competition or exclusivity losses.
REC FAQ
What was Recordati Industria Chimica e Farmaceutica SPA’s price range in the past 12 months?
Recordati Industria Chimica e Farmaceutica SPA lowest stock price was €43.76 and its highest was €55.35 in the past 12 months.
What is Recordati Industria Chimica e Farmaceutica SPA’s market cap?
Recordati Industria Chimica e Farmaceutica SPA’s market cap is €10.50B.
When is Recordati Industria Chimica e Farmaceutica SPA’s upcoming earnings report date?
Recordati Industria Chimica e Farmaceutica SPA’s upcoming earnings report date is Jul 28, 2026 which is in 45 days.
How were Recordati Industria Chimica e Farmaceutica SPA’s earnings last quarter?
Recordati Industria Chimica e Farmaceutica SPA released its earnings results on May 12, 2026. The company reported €0.732 earnings per share for the quarter, beating the consensus estimate of N/A by €0.732.
Is Recordati Industria Chimica e Farmaceutica SPA overvalued?
According to Wall Street analysts Recordati Industria Chimica e Farmaceutica SPA’s price is currently Undervalued.
Does Recordati Industria Chimica e Farmaceutica SPA pay dividends?
Recordati Industria Chimica e Farmaceutica SPA pays a Semiannually dividend of €0.71 which represents an annual dividend yield of 2.67%. See more information on Recordati Industria Chimica e Farmaceutica SPA dividends here
What is Recordati Industria Chimica e Farmaceutica SPA’s EPS estimate?
Recordati Industria Chimica e Farmaceutica SPA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Recordati Industria Chimica e Farmaceutica SPA have?
Recordati Industria Chimica e Farmaceutica SPA has 209,125,150 shares outstanding.
What happened to Recordati Industria Chimica e Farmaceutica SPA’s price movement after its last earnings report?
Recordati Industria Chimica e Farmaceutica SPA reported an EPS of €0.732 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.199%.
Which hedge fund is a major shareholder of Recordati Industria Chimica e Farmaceutica SPA?
Currently, no hedge funds are holding shares in IT:REC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica S.p.A., along with its various divisions, functions as a global pharmaceutical firm. Its core operations involve the research, development, production, commercialization, and worldwide distribution of medicinal products. The company's diverse portfolio covers an extensive spectrum of therapeutic areas, including cardiovascular health, dermatology, urology, anti-infectives, central nervous system disorders, gastrointestinal conditions, gynecology, musculoskeletal ailments, and pain management. Furthermore, Recordati supplies over-the-counter remedies, generic drugs, oncology treatments, and solutions for allergies, endocrine issues, and respiratory illnesses, encompassing even ear, nose, and throat preparations. Complementing its pharmaceutical offerings are nutritional products, cosmetics, dietary supplements, and medical devices. Additionally, the firm is a prominent provider of treatments for rare diseases and produces specialized pharmaceutical chemicals, such as active pharmaceutical ingredients (APIs), intermediates, and complex chemical syntheses. Established in Milan, Italy, in 1926, Recordati Industria Chimica e Farmaceutica S.p.A. currently operates as a subsidiary of Rossini S.à R.L.
REC Stock 12 Month Forecast
Average Price Target
€57.50
▲(14.09% Upside)
Technical Analysis
Options Prices
Currently, No data available
---